{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T08:57:11Z","timestamp":1772269031906,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T00:00:00Z","timestamp":1447977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T00:00:00Z","timestamp":1447977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pancreatic cancer is the most aggressive malignant disease, ranking as the fourth leading cause of cancer-related death among men and women in the United States. Interferon alpha (IFN\u03b1) has been used to treat pancreatic cancer, but its clinical application has been significantly hindered due to the low antitumor activity. We used a \u201ccDNA in-frame fragment library\u201d screening approach to identify short peptides that potentiate the antitumor activity of interferons. A short positively charged peptide derived from the C-terminus of placental growth factor-2 (PLGF-2) was selected to enhance the activity of IFN\u03b1. For this, we constructed a synthetic interferon hybrid molecule (SIF\u03b1) by fusing the positively charged PLGF-2 peptide to the C-terminus of the human IFN\u03b1. Using human pancreatic cell lines (ASPC and CFPAC1) as a model system, we found that SIF\u03b1 exhibited a significantly higher activity than did the wild-type IFN\u03b1 in inhibiting the tumor cell growth. The enhanced activity of the synthetic SIF\u03b1 was associated with the activation of interferon pathway target genes and the increased binding of cell membrane receptor. This study demonstrates the potential of a synthetic SIF\u03b1 as a novel antitumor agent.<\/jats:p>","DOI":"10.1038\/srep16975","type":"journal-article","created":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T11:09:58Z","timestamp":1448017798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antitumor potential of a synthetic interferon-alpha\/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells"],"prefix":"10.1038","volume":"5","author":[{"given":"Hongmei","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naifei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haofan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Fan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,20]]},"reference":[{"key":"BFsrep16975_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3322\/caac.20121","volume":"61","author":"R Siegel","year":"2011","unstructured":"Siegel, R., Ward, E., Brawley, O. & Jemal, A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61, 212\u2013236 (2011).","journal-title":"CA Cancer J Clin"},{"key":"BFsrep16975_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J Clin 60, 277\u2013300 (2010).","journal-title":"CA Cancer J Clin"},{"key":"BFsrep16975_CR3","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo, M. Pancreatic cancer. N Engl J Med 362, 1605\u20131617 (2010).","journal-title":"N Engl J Med"},{"key":"BFsrep16975_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364, 1817\u20131825 (2011).","journal-title":"N Engl J Med"},{"key":"BFsrep16975_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369, 1691\u20131703 (2013).","journal-title":"N Engl J Med"},{"key":"BFsrep16975_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/SLA.0b013e31805d0788","volume":"245","author":"PA Clavien","year":"2007","unstructured":"Clavien, P. A. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg 245, 843\u2013845 (2007).","journal-title":"Ann Surg"},{"key":"BFsrep16975_CR7","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/01.sla.0000245829.00977.45","volume":"245","author":"CM Lo","year":"2007","unstructured":"Lo, C. M. et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245, 831\u2013842 (2007).","journal-title":"Ann Surg"},{"key":"BFsrep16975_CR8","first-page":"1499","volume":"28","author":"K Hoffmann","year":"2008","unstructured":"Hoffmann, K., Mehrle, S., Schmidt, J., Buchler, M. W. & Marten, A. Interferon-alpha restitutes the chemosensitivity in pancreatic cancer. Anticancer Res 28, 1499\u20131507 (2008).","journal-title":"Anticancer Res"},{"key":"BFsrep16975_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","volume":"27","author":"S Sleijfer","year":"2005","unstructured":"Sleijfer, S., Bannink, M., Van Gool, A. R., Kruit, W. H. & Stoter, G. Side effects of interferon-alpha therapy. Pharm World Sci 27, 423\u2013431 (2005).","journal-title":"Pharm World Sci"},{"key":"BFsrep16975_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","volume":"6","author":"E Jonasch","year":"2001","unstructured":"Jonasch, E. & Haluska, F. G. Interferon in oncological practice: review of interferon biology, clinical applications and toxicities. Oncologist 6, 34\u201355 (2001).","journal-title":"Oncologist"},{"key":"BFsrep16975_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1126\/science.1247663","volume":"343","author":"MM Martino","year":"2014","unstructured":"Martino, M. M. et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science 343, 885\u2013888 (2014).","journal-title":"Science"},{"key":"BFsrep16975_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nature13320","volume":"510","author":"PK Mazur","year":"2014","unstructured":"Mazur, P.K. et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 510, 283\u2013283 (2014).","journal-title":"Nature"},{"key":"BFsrep16975_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.stem.2013.05.012","volume":"13","author":"H Zhang","year":"2013","unstructured":"Zhang, H. et al. Intrachromosomal Looping Is Required for Activation of Endogenous Pluripotency Genes during Reprogramming. Cell Stem Cell 13, 30\u201335 (2013).","journal-title":"Cell Stem Cell"},{"key":"BFsrep16975_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1083\/jcb.201304152","volume":"204","author":"H Zhang","year":"2014","unstructured":"Zhang, H. et al. Long noncoding RNA-mediated intrachromosomal interactions promote imprinting at the Kcnq1 locus. J Cell Biol 204, 61\u201375 (2014).","journal-title":"J Cell Biol"},{"key":"BFsrep16975_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1083\/jcb.201101021","volume":"193","author":"H Zhang","year":"2011","unstructured":"Zhang, H. et al. Interruption of intrachromosomal looping by CTCF decoy proteins abrogates genomic imprinting of human insulin-like growth factor II. J Cell Biol 193, 475\u2013487 (2011).","journal-title":"J Cell Biol"},{"key":"BFsrep16975_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1756-8935-7-20","volume":"7","author":"AN Ma","year":"2014","unstructured":"Ma, A. N. et al. Targeted gene suppression by inducing de novo DNA methylation in the gene promoter. Epigenetics Chromatin 7, 20 (2014).","journal-title":"Epigenetics Chromatin"},{"key":"BFsrep16975_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nmeth.3213","volume":"12","author":"J Yang","year":"2015","unstructured":"Yang, J. et al. The I-TASSER Suite: protein structure and function prediction. Nat Methods 12, 7\u20138 (2015).","journal-title":"Nat Methods"},{"key":"BFsrep16975_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nprot.2010.5","volume":"5","author":"A Roy","year":"2010","unstructured":"Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5, 725\u2013738 (2010).","journal-title":"Nat Protoc"},{"key":"BFsrep16975_CR19","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1002\/ijc.28922","volume":"135","author":"H Wang","year":"2014","unstructured":"Wang, H. et al. An intragenic long noncoding RNA interacts epigenetically with the RUNX1 promoter and enhancer chromatin DNA in hematopoietic malignancies. Int J Cancer 135, 2783\u20132794 (2014).","journal-title":"Int J Cancer"},{"key":"BFsrep16975_CR20","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/ijc.28487","volume":"134","author":"S Zhang","year":"2014","unstructured":"Zhang, S. et al. Epigenetic reprogramming reverses the malignant epigenotype of the MMP\/TIMP axis genes in tumor cells. Int J Cancer 134, 1583\u20131594 (2014).","journal-title":"Int J Cancer"},{"key":"BFsrep16975_CR21","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.1128\/MCB.00204-08","volume":"28","author":"T Li","year":"2008","unstructured":"Li, T. et al. CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex-2 intrachromosomal loop. Mol Cell Biol 28, 6473\u20136482 (2008).","journal-title":"Mol Cell Biol"},{"key":"BFsrep16975_CR22","doi-asserted-by":"publisher","first-page":"9588","DOI":"10.1093\/nar\/gku549","volume":"42","author":"J Sun","year":"2014","unstructured":"Sun, J. et al. A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies. Nucleic Acids Res 42, 9588\u20139601 (2014).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep16975_CR23","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/leu.2008.263","volume":"22","author":"AJ Novak","year":"2008","unstructured":"Novak, A. J. et al. A role for IFN-lambda1 in multiple myeloma B cell growth. Leukemia 22, 2240\u20132246 (2008).","journal-title":"Leukemia"},{"key":"BFsrep16975_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/jir.2009.0031","volume":"30","author":"Q Xue","year":"2010","unstructured":"Xue, Q., Yang, L., Liu, X. & Liu, W. Molecular characterization of feline type I interferon receptor 2. J Interferon Cytokine Res 30, 81\u201388 (2010).","journal-title":"J Interferon Cytokine Res"},{"key":"BFsrep16975_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/hmg\/ddt405","volume":"23","author":"T Li","year":"2014","unstructured":"Li, T. et al. Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor cell lines. Hum Mol Genet 23, 117\u2013128 (2014).","journal-title":"Hum Mol Genet"},{"key":"BFsrep16975_CR26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nrd2422","volume":"6","author":"EC Borden","year":"2007","unstructured":"Borden, E. C. et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6, 975\u2013990 (2007).","journal-title":"Nat Rev Drug Discov"},{"key":"BFsrep16975_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0065-2776(07)96002-2","volume":"96","author":"JR Schoenborn","year":"2007","unstructured":"Schoenborn, J. R. & Wilson, C. B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96, 41\u2013101 (2007).","journal-title":"Adv Immunol"},{"key":"BFsrep16975_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev.immunol.15.1.563","volume":"15","author":"EA Bach","year":"1997","unstructured":"Bach, E. A., Aguet, M. & Schreiber, R. D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 15, 563\u2013591 (1997).","journal-title":"Annu Rev Immunol"},{"key":"BFsrep16975_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1146\/annurev.bi.56.070187.003455","volume":"56","author":"S Pestka","year":"1987","unstructured":"Pestka, S., Langer, J. A., Zoon, K. C. & Samuel, C. E. Interferons and their actions. Annu Rev Biochem 56, 727\u2013777 (1987).","journal-title":"Annu Rev Biochem"},{"key":"BFsrep16975_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","volume":"67","author":"GR Stark","year":"1998","unstructured":"Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons. Annu Rev Biochem 67, 227\u2013264 (1998).","journal-title":"Annu Rev Biochem"},{"key":"BFsrep16975_CR31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1462-5822.2006.00716.x","volume":"8","author":"A Takaoka","year":"2006","unstructured":"Takaoka, A. & Yanai, H. Interferon signalling network in innate defence. Cell Microbiol 8, 907\u2013922 (2006).","journal-title":"Cell Microbiol"},{"key":"BFsrep16975_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fimmu.2013.00267","volume":"4","author":"CM Blouin","year":"2013","unstructured":"Blouin, C. M. & Lamaze, C. Interferon gamma receptor: the beginning of the journey. Front Immunol 4, 267 (2013).","journal-title":"Front Immunol"},{"key":"BFsrep16975_CR33","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1021\/nn4057269","volume":"8","author":"DM Copolovici","year":"2014","unstructured":"Copolovici, D. M., Langel, K., Eriste, E. & Langel, U. Cell-penetrating peptides: design, synthesis and applications. ACS Nano 8, 1972\u20131994 (2014).","journal-title":"ACS Nano"},{"key":"BFsrep16975_CR34","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.2174\/1381612811319160006","volume":"19","author":"S Trabulo","year":"2013","unstructured":"Trabulo, S. et al. Cell-penetrating peptides as nucleic acid delivery systems: from biophysics to biological applications. Curr Pharm Des 19, 2895\u20132923 (2013).","journal-title":"Curr Pharm Des"},{"key":"BFsrep16975_CR35","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00018-005-5109-0","volume":"62","author":"S Deshayes","year":"2005","unstructured":"Deshayes, S., Morris, M. C., Divita, G. & Heitz, F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 62, 1839\u20131849 (2005).","journal-title":"Cell Mol Life Sci"},{"key":"BFsrep16975_CR36","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/0092-8674(88)90262-0","volume":"55","author":"M Green","year":"1988","unstructured":"Green, M. & Loewenstein, P. M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55, 1179\u20131188 (1988).","journal-title":"Cell"},{"key":"BFsrep16975_CR37","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1093\/nar\/25.14.2730","volume":"25","author":"MC Morris","year":"1997","unstructured":"Morris, M. C., Vidal, P., Chaloin, L., Heitz, F. & Divita, G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 25, 2730\u20132736 (1997).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep16975_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/sj.gt.3300838","volume":"6","author":"MS Dilber","year":"1999","unstructured":"Dilber, M. S. et al. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 6, 12\u201321 (1999).","journal-title":"Gene Ther"},{"key":"BFsrep16975_CR39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2174\/1389201015666140617093331","volume":"15","author":"YS Choi","year":"2014","unstructured":"Choi, Y. S. & David, A. E. Cell penetrating peptides and the mechanisms for intracellular entry. Curr Pharm Biotechnol 15, 192\u2013199 (2014).","journal-title":"Curr Pharm Biotechnol"},{"key":"BFsrep16975_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.peptides.2014.04.015","volume":"57","author":"SM Farkhani","year":"2014","unstructured":"Farkhani, S. M. et al. Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides 57, 78\u201394 (2014).","journal-title":"Peptides"},{"key":"BFsrep16975_CR41","doi-asserted-by":"publisher","first-page":"414729","DOI":"10.1155\/2011\/414729","volume":"2011","author":"F Madani","year":"2011","unstructured":"Madani, F., Lindberg, S., Langel, U., Futaki, S. & Graslund, A. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys 2011, 414729 (2011).","journal-title":"J Biophys"},{"key":"BFsrep16975_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1524-475X.2011.00673.x","volume":"19","author":"GS Schultz","year":"2011","unstructured":"Schultz, G. S., Davidson, J. M., Kirsner, R. S., Bornstein, P. & Herman, I. M. Dynamic reciprocity in the wound microenvironment. Wound Repair Regen 19, 134\u2013148 (2011).","journal-title":"Wound Repair Regen"},{"key":"BFsrep16975_CR43","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S0344-0338(11)80996-9","volume":"190","author":"H Lortat-Jacob","year":"1994","unstructured":"Lortat-Jacob, H., Esterre, P. & Grimaud, J. A. Interferon-gamma, an anti-fibrogenic cytokine which binds to heparan sulfate. Pathol Res Pract 190, 920\u2013922 (1994).","journal-title":"Pathol Res Pract"},{"key":"BFsrep16975_CR44","first-page":"343","volume":"8","author":"O Sangfelt","year":"1997","unstructured":"Sangfelt, O. et al. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ 8, 343\u2013352 (1997).","journal-title":"Cell Growth Differ"},{"key":"BFsrep16975_CR45","first-page":"974","volume":"83","author":"F Luchetti","year":"1998","unstructured":"Luchetti, F. et al. The K562 chronic myeloid leukemia cell line undergoes apoptosis in response to interferon-alpha. Haematologica 83, 974\u2013980 (1998).","journal-title":"Haematologica"},{"key":"BFsrep16975_CR46","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/blood.V93.10.3309.410k04_3309_3316","volume":"93","author":"C Dai","year":"1999","unstructured":"Dai, C. & Krantz, S. B. Interferon gamma induces upregulation and activation of caspases 1, 3 and 8 to produce apoptosis in human erythroid progenitor cells. Blood 93, 3309\u20133316 (1999).","journal-title":"Blood"},{"key":"BFsrep16975_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1089\/jir.2014.0157","volume":"35","author":"S Booy","year":"2015","unstructured":"Booy, S., Hofland, L. & van Eijck, C. Potentials of interferon therapy in the treatment of pancreatic cancer. J Interferon Cytokine Res 35, 327\u2013339 (2015).","journal-title":"J Interferon Cytokine Res"},{"key":"BFsrep16975_CR48","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/sj.onc.1205179","volume":"21","author":"L Thyrell","year":"2002","unstructured":"Thyrell, L. et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 21, 1251\u20131262 (2002).","journal-title":"Oncogene"},{"key":"BFsrep16975_CR49","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.ejca.2005.03.022","volume":"41","author":"C Barton","year":"2005","unstructured":"Barton, C., Davies, D., Balkwill, F. & Burke, F. Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J Cancer 41, 1474\u20131486 (2005).","journal-title":"Eur J Cancer"},{"key":"BFsrep16975_CR50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.immuni.2007.06.009","volume":"27","author":"P Tailor","year":"2007","unstructured":"Tailor, P. et al. The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. Immunity 27, 228\u2013239 (2007).","journal-title":"Immunity"},{"key":"BFsrep16975_CR51","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/ni.1733","volume":"10","author":"G Mancuso","year":"2009","unstructured":"Mancuso, G. et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 10, 587\u2013594 (2009).","journal-title":"Nat Immunol"},{"key":"BFsrep16975_CR52","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1084\/jem.20101664","volume":"207","author":"GType Trinchieri","year":"2010","unstructured":"Trinchieri, G. Type I interferon: friend or foe? J Exp Med 207, 2053\u20132063 (2010).","journal-title":"J Exp Med"},{"key":"BFsrep16975_CR53","doi-asserted-by":"publisher","first-page":"23786","DOI":"10.1074\/jbc.M114.551879","volume":"289","author":"S Maeda","year":"2014","unstructured":"Maeda, S. et al. Interferon-alpha acts on the S\/G2\/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line. J Biol Chem 289, 23786\u201323795 (2014).","journal-title":"J Biol Chem"},{"key":"BFsrep16975_CR54","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1038\/sj.onc.1202609","volume":"18","author":"O Sangfelt","year":"1999","unstructured":"Sangfelt, O. et al. Molecular mechanisms underlying interferon-alpha-induced G0\/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 18, 2798\u20132810 (1999).","journal-title":"Oncogene"},{"key":"BFsrep16975_CR55","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.bcmd.2003.10.008","volume":"32","author":"D Grebenova","year":"2004","unstructured":"Grebenova, D. et al. Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis. Blood Cells Mol Dis 32, 262\u2013269 (2004).","journal-title":"Blood Cells Mol Dis"},{"key":"BFsrep16975_CR56","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1128\/MCB.16.7.3934","volume":"16","author":"N Tiefenbrun","year":"1996","unstructured":"Tiefenbrun, N. et al. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. Mol Cell Biol 16, 3934\u20133944 (1996).","journal-title":"Mol Cell Biol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep16975","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep16975.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep16975.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T18:50:29Z","timestamp":1672944629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep16975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,20]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,22]]}},"alternative-id":["BFsrep16975"],"URL":"https:\/\/doi.org\/10.1038\/srep16975","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,20]]},"assertion":[{"value":"18 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16975"}}